Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Solid Tumor, Bladder Cancer, Non-muscle-invasive Bladder Cancer
Interventions: Lerapolturev, 5% DDM; Biological · Other
Lead sponsor: Istari Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Myrtle Beach, South Carolina

Conditions: Noise Exposure, Noise-induced Hearing Loss, Noise; Adverse Effect, Mild Therapeutic Hypothermia, Cooling, Occupational Exposure, Occupational Health, Hidden Hearing Loss
Interventions: Cold pack-delivered mild therapeutic hypothermia; Device
Lead sponsor: Restorear Devices LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: High-risk Non-muscle Invasive Bladder Cancer
Interventions: Pembrolizumab, BCG; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2034
U.S. locations: 44
States / cities: Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 39 more

Conditions: Colon Cancer, Colon Polyp, Rectal Cancer, Diverticulitis, Prolapse, Rectal, Rectal Polyp, Inflammatory Bowel Diseases
Interventions: Single Port Robotic Colorectal Surgery; Device
Lead sponsor: Marks Colorectal Surgical Associates; Other
Eligibility: 18 Years to 95 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Wynnewood, Pennsylvania

Conditions: Pain, Postoperative
Interventions: Local anesthesia at incision site, Sham QL, Sham Local, QL; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Wrinkles, Rhytides
Interventions: TriActive+ RF; Device
Lead sponsor: El. En. SpA; Industry
Eligibility: 30 Years to 60 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Indianapolis, Indiana • New York, New York

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: Cindy Cisneros; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 15,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: San Jose, California

Conditions: Ductal Breast Carcinoma in Situ, Invasive Ductal Breast Carcinoma, Invasive Lobular Breast Carcinoma, Lobular Breast Carcinoma in Situ, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer
Interventions: Behavioral dietary intervention, Therapeutic conventional surgery, Radiation therapy, Counseling intervention, Quality-of-life assessment; Behavioral · Procedure · Radiation + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prematurity, BPD - Bronchopulmonary Dysplasia, Respiratory Distress Syndrome, Newborn
Interventions: Volume Targeted Ventilation (VTV) using the Philips Respironics NM3 monitor, Tidal Volume Measurement using the Philips Respironics NM3 monitor; Device
Lead sponsor: Baystate Medical Center; Other
Eligibility: 5 Minutes to 60 Minutes
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Prostate Cancer (Diagnosis)
Interventions: Not listed
Lead sponsor: Xiangya Hospital of Central South University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: intermittent theta burst stimulation (iTBS) with sham and then active stimulation over bicep muscle, intermittent theta burst stimulation (iTBS) with sham and then active stimulation over finger muscle; Device
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Neuropathy;Peripheral, Limb Ischemia
Interventions: Lower-Extremity Perfusion Monitoring; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Cerebral Palsy
Interventions: pneuRIP; Device
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 5 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Epilepsy
Interventions: radiosurgery, temporal lobectomy; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 13
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more

Conditions: Aortic Valve Stenosis, Aortic Valve Stenosis With Insufficiency, Regurgitation, Aortic Valve, Aortic Valve Incompetence
Interventions: EDWARDS INTUITY valve; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: 18 Years and older
Enrollment: 934 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 29
States / cities: Los Angeles, California • Newport Beach, California • Palo Alto, California + 24 more

Conditions: Ischemic Stroke
Interventions: Non-invasive ventilatory treatment with auto-BPAP; Device
Lead sponsor: Technische Universität Dresden; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Candidiasis, Invasive, Candidemia
Interventions: SCY-078; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Jersey City, New Jersey

Conditions: Urinary Bladder Cancer, Muscle-invasive
Interventions: Pembrolizumab, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Enfortumab Vedotin; Drug · Procedure
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 595 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 39
States / cities: Mobile, Alabama • Little Rock, Arkansas • Fullerton, California + 31 more

Conditions: Graft Rejection, Heart Diseases
Interventions: Endomyocardial biopsy, AlloMap Molecular Testing; Procedure
Lead sponsor: XDx; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Breast Cancer
Interventions: Letrozole, Tamoxifen, Palbociclib, Endocrine Therapy; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2031
U.S. locations: 11
States / cities: Stamford, Connecticut • Brewer, Maine • Boston, Massachusetts + 5 more

Conditions: Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases, Coronary Heart Disease, CHD, CVD, CAD
Interventions: Corus CAD (ASGES); Diagnostic Test
Lead sponsor: CardioDx; Industry
Eligibility: 21 Years and older
Enrollment: 667 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Localized Intermediate Risk Prostate Lesions
Interventions: ExAblate MR Guided Focused Ultrasound; Device
Lead sponsor: InSightec; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Stanford, California + 5 more

Conditions: Breast Cancer, Ductal Carcinoma in Situ
Interventions: Intranasal Oxytocin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Invasive Mammary Carcinoma, Metastatic Breast Cancer
Interventions: Capecitabine, Endocrine-therapy, MammoPrint ® and BluePrint assays; Drug · Other
Lead sponsor: Sonya Reid; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 4
States / cities: Birmingham, Alabama • Memphis, Tennessee • Nashville, Tennessee + 1 more

Search by objective public record fields.

LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors

Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Feasibility and Safety of Single Port Robot in Colorectal Procedures

The Role of Quadratus Lumborum Blocks Following Minimally Invasive Hysterectomy

TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides

Development of a Non-invasive Prenatal Test

Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy

Feasibility and Impact of Volume Targeted Ventilation in the Delivery Room

Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT

The Effect of Brain Anatomy on the Efficacy of Brain Stimulation Therapy

Feasibility and Clinical Utility of Paired Non-Invasive Hemodynamic and Tissue Oximetry Monitoring to Detect Limb Ischemia in Lithotomy-Positioned Surgeries

Non-Invasive Measurement of Pulmonary Dysfunction in Children With Cerebral Palsy

Radiosurgery or Open Surgery for Epilepsy Trial

Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve

Reversal of the Neurological Deficit in Acute Stroke With the Signal of Efficacy Trial of Auto BPAP to Limit Damage From Suspected Sleep Apnea

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

A Comparison of AlloMap Molecular Testing and Traditional Biopsy-based Surveillance for Heart Transplant Rejection Early Post-transplantation

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Clinical Utility of an Age, Sex, and Gene Expression Score (ASGES or Corus CAD) in African American Patients.

Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions

Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort